OncoGenex Lung-Cancer Drug Shines in Study
Posted on: Wednesday, 3 May 2006, 12:00 CDT
OncoGenex said Wednesday its non-small cell lung cancer treatment OGX-011 showed promising results in a phase 1 study.
The one-year survival rate for the nine patients that received OGX-011 in combination with standard chemotherapy agents was 67 percent. All except one patient showed a partial response or stable disease.
These rates compare quite favorably with the median survival of 8 to 11 months and the one-year survival rates of 32 to 45 percent reported in eight randomized phase 3 studies involving over 1500 patients using a platinum-based regimen plus gemcitabine as first-line chemotherapy for NSCLC, Janessa Laskin, study chair and a medical oncologist at BC Cancer Agency, said in a statement issued by OncoGenex.
OGX-011, which OncoGenex is developing with Isis, was well tolerated, and the side effects were similar to that of standard chemotherapy agents. The most common adverse events included constipation, change in taste, fatigue and chills. Hematological problems and low sodium also were common in study participants.
Source: United Press International
Related Articles
- FDA Grants Additional Fast Track Designation for OGX-011 in Combination with First Line Chemotherapy
- OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
- OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
- OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
- OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
- FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011
- OncoGenex Increases Economic Interest in Lead Cancer Drug OGX-011
- OncoGenex Reports That Low Serum Clusterin Levels Were Predictive of Survival in Preliminary Analyses of Phase 2 Study of Lead Drug Candidate OGX-011
- OncoGenex Reports Updated Survival Data on OGX-011 in a Second-Line Chemotherapy Trial for Patients With Prostate Cancer
- Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer
 |
 |
User Comments (0)
RSS Feeds